Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist

被引:91
作者
Kassack, MU
Braun, K
Ganso, M
Ullmann, H
Nickel, P
Böing, B
Müller, G
Lambrecht, G
机构
[1] Univ Bonn, Inst Pharmaceut, D-53121 Bonn, Germany
[2] Univ Frankfurt, Bioctr Niederursel, Dept Pharmacol, D-60439 Frankfurt, Germany
关键词
P2X; P2Y; NF449; NF279; NF023; suramin;
D O I
10.1016/j.ejmech.2004.01.007
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
NF449 [4,4',4"-4'''-(carbonylbis(imino-5,1,3-benzenetriyl-bis(carbonylimino)))tetrakisbenzene-1,3-disulfonic acid-octasodiumsalt)] was recently described to inhibit recombinant rP2X(1) receptors (Naunyn Schmiedeberg's Arch. Pharmacol. 364 (2001) 285). The purpose of this study was to examine structure-activity-relationships at P2 receptors of a series of NF449 analogues. Thus, compounds containing various arylaminemono-, di-, or trisulfonic acids and a replacement of the central urea bridge were synthesized. NF449 displayed a pIC(50) at P2X(I) receptors (rat vas deferens) of 6.31 +/- 0.04 being at least 19-fold more potent at P2X(1) than at P2X(3), P2Y(1), P2Y(2), or P2Y(11). Any deletion or chance of position of sulfonic acid groups or replacing the central urea bond by the bisamide of terephthalic acid reduced the potency at P2X(1) by at least 90%. All compounds were very weak antagonists at P2Y(2) or P2Y(11) receptors (pIC(50) < 4.5). In conclusion, NF449 remains the most potent and selective P2X(1) antagonist known. Potential lead compounds among the suramin class for P2X(3) (16d) and P2Y(1) (16a) receptors were identified. (C) 2004 Elsevier SAS. All rights reserved.
引用
收藏
页码:345 / 357
页数:13
相关论文
共 37 条
  • [1] PURINOCEPTORS - ARE THERE FAMILIES OF P2X AND P2Y PURINOCEPTORS
    ABBRACCHIO, MP
    BURNSTOCK, G
    [J]. PHARMACOLOGY & THERAPEUTICS, 1994, 64 (03) : 445 - 475
  • [2] NF449:: a subnanomolar potency antagonist at recombinant rat P2X1 receptors
    Braun, K
    Rettinger, J
    Ganso, M
    Kassack, M
    Hildebrandt, C
    Ullmann, H
    Nickel, P
    Schmalzing, G
    Lambrecht, G
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 364 (03) : 285 - 290
  • [3] P-2-purinoceptor antagonists .3. Blockade of P-2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin
    Bultmann, R
    Wittenburg, H
    Pause, B
    Kurz, G
    Nickel, P
    Starke, K
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1996, 354 (04) : 498 - 504
  • [4] Potential therapeutic targets in the rapidly expanding field of purinergic signalling
    Burnstock, G
    [J]. CLINICAL MEDICINE, 2002, 2 (01) : 45 - 53
  • [5] A G protein-coupled receptor for UDP-glucose
    Chambers, JK
    Macdonald, LE
    Sarau, HM
    Ames, RS
    Freeman, K
    Foley, JJ
    Zhu, Y
    McLaughlin, MM
    Murdock, P
    McMillan, L
    Trill, J
    Swift, A
    Aiyar, N
    Taylor, P
    Vawter, L
    Naheed, S
    Szekeres, P
    Hervieu, G
    Scott, C
    Watson, JM
    Murphy, AJ
    Duzic, E
    Klein, C
    Bergsma, DJ
    Wilson, S
    Livi, GP
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (15) : 10767 - 10771
  • [6] Pharmacological characterization of the human P2Y11 receptor
    Communi, D
    Robaye, B
    Boeynaems, JM
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (06) : 1199 - 1206
  • [7] Identification of a novel human ADP receptor coupled to Gi
    Communi, D
    Gonzalez, NS
    Detheux, M
    Brézillon, S
    Lannoy, V
    Parmentier, M
    Boeynaems, JM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (44) : 41479 - 41485
  • [8] NF279: a novel potent and selective antagonist of P2X receptor-mediated responses
    Damer, S
    Niebel, B
    Czeche, S
    Nickel, P
    Ardanuy, U
    Schmalzing, G
    Rettinger, J
    Mutschler, E
    Lambrecht, G
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 350 (01) : R5 - R6
  • [9] Nucleotide receptors: an emerging family of regulatory molecules in blood cells
    Di Virgilio, F
    Chiozzi, P
    Ferrari, D
    Falzoni, S
    Sanz, JM
    Morelli, A
    Torboli, M
    Bolognesi, G
    Baricordi, OR
    [J]. BLOOD, 2001, 97 (03) : 587 - 600
  • [10] SURAMIN - A REVERSIBLE P2-PURINOCEPTOR ANTAGONIST IN THE MOUSE VASDEFERENS
    DUNN, PM
    BLAKELEY, AGH
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1988, 93 (02) : 243 - 245